01:32:19 EDT Fri 14 Jun 2024
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save
Diagnos Inc (3)
Symbol ADK
Shares Issued 74,357,028
Close 2024-01-16 C$ 0.395
Market Cap C$ 29,371,026
Recent Sedar Documents

Diagnos appoints Couture as COO, grants option

2024-01-16 16:16 ET - News Release

Mr. Andre Larente reports

DIAGNOS APPOINTS NEW CHIEF OPERATING OFFICER

Diagnos Inc. has appointed Yves-Stephane Couture as chief operating officer. As part of his duties, Mr. Couture will be responsible for the continuous development of its flagship product CARA, as well as its commercialization worldwide.

Mr. Couture joined Diagnos in 2017. Since then, he has been a key asset in the development of artificial-intelligence-based solutions used by optometrists and ophthalmologists to detect and classify multiple illnesses through the analysis of fundus pictures, as well as retina scans. Mr. Couture strongly believes that artificial-intelligence-based solutions is key to solving some of the most important challenges facing health care providers in the delivery of care to patients.

"By his actions, Yves-Stephane has shown total dedication to the success of the corporation, and, on behalf of our employees and directors, I wish him the best in his continued efforts to grow our revenues," said Andre Larente, president of Diagnos.

Mr. Couture's new role is effective Jan. 15, 2024.

Prior to joining Diagnos, Mr. Couture led sales and implementation teams with large information technology and telecommunication companies, such as Alcatel-Lucent and Teleglobe, where he was in charge of commercializing and implementing complex infrastructure solutions for health care providers and hospitals. Mr. Couture holds a bachelor's degree in administration from the University of Sherbrooke, where he also received a master's degree in marketing.

The board of directors of the corporation has approved a grant of 100,000 stock options to Mr. Couture. The date of the grant is Jan. 15, 2024. Stock options vest at 50 per cent per year, commencing with the first anniversary of the grant. The exercise price of the stock options has been established at 41 cents per common share. The expiry date to which the stock options can be exercised has been fixed to Jan. 15, 2029.

All moneys quoted in this press release shall be stated and paid in lawful money of Canada.

About Diagnos Inc.

Diagnos is a publicly traded Canadian corporation dedicated to early detection of critical health problems based on its Flaire artificial intelligence platform. Flaire allows for quick modifying and developing of applications such as CARA (computer assisted retina analysis). CARA's image enhancement algorithms provide sharper, clearer and easier-to-analyze retinal images. CARA is a cost-effective tool for real-time screening of large volumes of patients.

We seek Safe Harbor.

© 2024 Canjex Publishing Ltd. All rights reserved.